A third trial demonstrated that a combination of 5-FU and MMC was shown to be superior to 5-FU alone when combined with radiation.
Interestingly, this second trial demonstrated a survival benefit in critically ill trauma patients randomized to receive EPO treatment: at day 29 (deaths: placebo 8.9% vs. EPO 4.1%) and day 42 (deaths: placebo 10.4% vs. EPO 4.8%).
The first trial demonstrated a superior, but non-significant, survival benefit for patients treated with the combination of STZ and 5-fluorouracil (5-FU) compared with STZ alone, 304 while the second showed better survival for the combination of STZ and doxorubicin (DOX; 26 months) over single-agent chlorozotocin (18 months) or the 5-FU/STZ combination (17 months).
One of the first trials demonstrated that the addition of aprepitant 400 mg on day 1 of chemotherapy significantly reduced the frequency of both acute and delayed emesis compared with a standard regimen of granisetron and dexamethasone (Campos et al. 2001).
A second trial, the Oslo II study, demonstrated that the recall rates were statistically higher for FFDM than SFM.
A second trial in insulin-treated patients also demonstrated improved cardiovascular outcomes in patients randomised to metformin relative to placebo [ 53].
Recently, a phase I trial demonstrated that the second generation Affibody In-ABY-025 has improved distribution, dosimetry and accuracy in assessing patients with HER2-positive and HER2-negative metastatic breast cancer.
A third trial started from July 2013 to test demonstrated brain amyloid burden, and data is expected to be read out in December 2016.
Recently, the first randomized controlled trial demonstrated the feasibility and safety of balanced xenon anaesthesia for cardiac surgery [ 24].
A first-in-human, phase I trial demonstrated evidence of activity in patients with advanced solid tumors 12. Stable disease or better was achieved in 47% of patients, including two patients who achieved radiographic improvement for more than 18 months following treatment.
